Purchase of Ordinary Shares by Investment Adviser
25 April 2023
LEI 213800RG7JNX7K8F7525
Life Science REIT plc
("Life Science REIT" or the "Company")
Purchase of Ordinary Shares by Investment Adviser
Ironstone Asset Management acquire 600,000 ordinary shares in Life Science REIT plc
The Board of Life Science REIT (LSE: LABS), the real estate investment trust focused on UK life science properties, is pleased to announce that, in accordance with the terms of the Investment Advisory Agreement ("IAA") between the Company, G10 Capital Limited and Ironstone Asset Management Limited (the "Investment Adviser"), the Company was notified on 24 April 2023 that the Investment Adviser has acquired 600,000 ordinary shares in the share capital of the Company ("Ordinary Shares") at a weighted average price of 66.18 pence per share for a total cost of £399,207.02.
The Ordinary Shares have been purchased pursuant to the IAA, details of which were disclosed in the prospectus published by the Company on 14 November 2022.
Following the purchase, the Investment Adviser has an interest in 600,000 Ordinary Shares, representing 0.17% of the Company's issued Ordinary Shares.
Simon Farnsworth, Managing Director of Ironstone Asset Management Ltd, the Company's Investment Adviser, said:
"The acquisition of Life Science REIT shares by Ironstone Asset Management not only fulfils an obligation from the Company's prospectus but also demonstrates our ongoing commitment to the Company's strategy and our confidence in the prospects of its portfolio."
Enquiries:
|
Link Company Matters Limited - Company Secretary |
|
|
|
|
|
|
|
|
Ironstone Asset Management - Investment Adviser |
|
|
Simon Farnsworth / David Lewis / Joanna Waddingham |
via Buchanan below |
|
|
|
|
Panmure Gordon (UK) Limited -Joint Corporate Broker |
+44 20 7886 2500 |
|
Alex Collins / Tom Scrivens |
|
|
|
|
|
Jefferies International Limited - Joint Corporate Broker |
+44 20 7029 8000 |
|
Tom Yeadon / Andrew Morris / Oliver Nott / Harry Randall |
|
|
|
|
|
G10 Capital Limited - AIFM |
+44 20 7397 5450 |
|
Verity Morgan-Jones / Paul Cowland |
|
|
|
|
|
|
|
|
Buchanan - Financial PR |
+44 20 7466 5000 |
|
Mark Court / Henry Wilson / Verity Parker |
|
|
|
Notes to editors
Life Science REIT plc is a specialist property business focused on the UK's growing life science sector. The Company's portfolio of assets is located across the "Golden Triangle" of research and development hubs in Oxford, Cambridge and London's Knowledge Quarter and its strategic vision is to become the property provider of choice for life science companies in the UK.
Life Science REIT is addressing the acute demand-supply imbalance for laboratory space in the "Golden Triangle", which is characterised by low vacancy rates and prime rental increases. The UK life science sector itself is benefiting from a buoyant early-stage funding environment, driving demand for laboratory space.
The Company's diverse portfolio of assets ranges from a 20-acre science park currently under development through to fully let buildings, with an important part of the Company's strategy being the conversion of existing properties to laboratory space.
The Company's investment policy is focused on capital growth whilst also providing a growing level of income.
Life Science REIT trades on the Main Market of the London Stock Exchange under the ticker LABS.
Further information is available at https://lifesciencereit.co.uk. To sign up for email alerts, please visit https://lifesciencereit.co.uk/investors/.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 6 hours ago Luceco
- 6 hours ago Helios Towers
- 6 hours ago Wise Class A
- 6 hours ago EDX Medical Group Plc
- 7 hours ago Naked Wines